Zoom News : Jun 22, 2021, 04:23 PM
Big news related to India's indigenous corona vaccine Covaxin has come out. In the third phase trial data, it has proved to be 77.8 percent effective. This report has been submitted to the Central Government Committee on behalf of Bharat Biotech. It was reported in the morning that Bharat Biotech, which makes the vaccine, has shared the clinical trial data from the third phase related to it with the Drug Controller General of India (DCGI).After receiving the third phase data, the Subject Expert Committee (SEC) had a meeting today on Tuesday. In this, this information has been handed over by Covaccine. The SEC has seen the data provided by Bharat Biotech. But at the moment no acceptance or rejection has been given. In further processing, the SEC will hand over its data to DCGILet us tell you that Covaccine was approved for emergency use about 5 months ago without the results of these trials. There was also a lot of controversy when the trial results were approved without approval.At present, a vaccination campaign is being conducted in India with two corona vaccines. The first is AstraZeneca's corona vaccine. Which is being made by the name of Serum Institute Covishield. The second is Bharat Biotech's Covaccine. This is the first fully Indian vaccine. When the corona was at its peak and the vaccination campaign was to start soon, then Kovishield and Covaccine were approved for emergency use. Then a lot of questions were raised about the approval of Covaccine without the results of the Phase III trial.
However, no serious side effects of Covaccine have been reported after the start of vaccination. Bharat Biotech has also said that it is also conducting Phase IV trials. At present, the vaccine has not found a place in the vaccine list for emergency use issued by the WHO. Efforts are on in this regard.Bharat Biotech said last month that it expects the vaccine to find a place in the WHO's list of approvals for emergency use between July and September.
However, no serious side effects of Covaccine have been reported after the start of vaccination. Bharat Biotech has also said that it is also conducting Phase IV trials. At present, the vaccine has not found a place in the vaccine list for emergency use issued by the WHO. Efforts are on in this regard.Bharat Biotech said last month that it expects the vaccine to find a place in the WHO's list of approvals for emergency use between July and September.